AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curis and Aurigene Announce Amendment of Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for 3-Aminopyrrolidine dihydrochloride

    Menu

    3-Aminopyrrolidine dihydrochloride

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Curis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Curis and Aurigene Announce Amendment of Collaboration

              Details:

              Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer. Curis retains U.S., E.U., and rest of world rights to CA-170.

              Lead Product(s): 3-Aminopyrrolidine dihydrochloride

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Aurigene

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY